CMV: A warrior against leukemia?

Blood

Volumn 122, Issue 7, 2013, Pages 1101-1102

  Ljungman, Per ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; HUMAN; LEUKEMIA; LEUKEMIA RELAPSE; PRIMARY INFECTION; PRIORITY JOURNAL; SHORT SURVEY; ACUTE GRANULOCYTIC LEUKEMIA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MALE; NOTE; PHYSIOLOGY; TUMOR RECURRENCE; VIRUS ACTIVATION;

CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; MATRIX PROTEIN; PHOSPHOPROTEIN;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM RECURRENCE, LOCAL; PHOSPHOPROTEINS; VIRAL MATRIX PROTEINS; VIRUS ACTIVATION;

EID: 84887145602     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-508515     Document Type: Short Survey

References (10)

1. Green ML, Leisenring WM, Xie H, et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood. 2013; 122(7): 1316-1324.
2. Lönnqvist B., Ringdèn O, Ljungman P., Wahren B, Gahrton G. Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br J Haematol. 1986; 63(4): 671-679. (Pubitemid 16033605)
3. Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 2011; 118(5): 1402-1412.
4. Ito S, Pophali P, Co W., et al. CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML [published online ahead of print April 8, 2013]. Bone Marrow Transplant.
5. Söderberg-Nauclér C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997; 91(1): 119-126. (Pubitemid 27431318)
6. Kondo K, Xu J, Mocarski ES. Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc Natl Acad Sci USA. 1996; 93(20): 11137-11142. (Pubitemid 26333131)
7. Thomson KJ, Mackinnon S, Peggs KS. CMV-specific cellular therapy for acute myeloid leukemia? Blood. 2012; 119(4): 1088-1090.
8. Scheper W, van Dorp S, Kersting S, et al. gdT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia. 2013; 27(6): 1328-1338.
9. Marty FM, Ljungman P, Papanicolaou G.A., et al.; Maribavir 1263-300 Clinical Study Group. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011; 11(4): 284-292.
10. Kharfan-Dabaja M.A., Boeckh M, Wilck M.B., et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012; 12(4): 290-299.